JSH Co Ltd

JSH Co Ltd maintains a strong liquidity position with a current ratio of 2.21 and cash and equivalents of ¥810.82 million, which supports its operational flexibility. The company's debt-to-equity ratio of 0.23 indicates a conservative capital structure, with long-term debt of ¥469.96 million relative to total equity of ¥2.04 billion. Free cash flow is negative at ¥351.68 million, primarily due to capital expenditures of ¥645.05 million, suggesting ongoing investment in growth or operational expansion. Profitability metrics show a return on equity of 7.07% and a return on assets of 4.83%, which are below the industry median for Personal Services firms. This suggests that JSH Co Ltd is underperforming in terms of asset and equity utilization compared to its peers. The operating margin of 4.29% (¥170.15 million operating income on ¥3.97 billion revenue) is also below the industry median, indicating potential inefficiencies or pricing pressures. The company's revenue is concentrated in two segments: Home Medical Care and Regional Revitalization. The Home Medical Care segment is the primary revenue driver, though the exact contribution is not disclosed. The Regional Revitalization segment includes employment support and tourism, which may be more volatile and less scalable. No geographic diversification is reported, with all operations based in Japan, exposing the company to local economic and regulatory risks. Outlook for the current fiscal year shows a revenue growth of 3.2% year-over-year, with a net income growth of 1.8%. For the next fiscal year, revenue is projected to grow by 4.5%, and net income by 2.1%. These modest growth rates suggest a stable but not aggressive expansion strategy. The company's capital expenditures are expected to remain high, which may continue to pressure free cash flow. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's debt levels are manageable, and there is no evidence of near-term equity dilution. However, the negative free cash flow and high capital expenditures may pose long-term liquidity risks if not offset by revenue growth. The risk of dilution is low, with no recent or pending equity offerings reported. Recent events include the filing of the latest financial results, which show a revenue of ¥3.97 billion and an EPS of ¥25.67. No significant regulatory or operational events were disclosed in the latest filings. The company's focus on home medical care and regional revitalization aligns with demographic and policy trends in Japan, but the lack of geographic diversification remains a concern.